Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index; 74 of the 186 sources its claims cite were checked for support.
Abstract
Gene therapy has emerged as a research topic of choice in recent years. The eye in particular is one of few organs of the body for which gene therapy has received Food and Drug Administration approval, and it remains a field of great interest for gene therapy development. However, its associated immune and inflammatory reactions may render the treatment ineffective or harmful, which are of particular concern for the eyes due to their susceptibility to inflammation. The severity of immune and inflammatory reactions depends on the choice of vector and its route of administration. Furthermore, most preclinical and clinical studies have shown that the dose of vectors is correlated with the degree of humoral response and ocular inflammation. The route of administration directly impacts the degree of immune and inflammatory reaction. Subretinal delivery produces a weaker humoral response than the intravitreal route. However, some studies have demonstrated that the subretinal delivery induces a stronger inflammatory reaction. On the other hand, several instances of vision loss due to severe late onset intraocular inflammation were reported in a clinical trial involving intravitreal delivery of viral vectors. When compared with the intravitreal route, suprachoroidal gene delivery has been shown to produce weaker humoral response. However, unlike the subretinal space, the suprachoroidal space is not known to have immune privilege status. Inflammatory reactions following ocular gene therapy are typically mild and most clinical and preclinical studies have shown that they can be controlled with topical, local or systemic steroids. However, severe inflammatory responses may occur and require aggressive management to avoid permanent vision loss. Further investigations are required to elucidate and expand our knowledge of inflammatory reactions, and their optimal management, following ocular gene therapy.
Overview
CoChat Summary
TL;DR
This review summarizes ocular gene therapy vectors, delivery routes, and the immune/inflammatory responses that can limit efficacy or cause harm. It concludes that reactions are usually mild and steroid-responsive, but high-dose intravitreal therapy can cause late-onset sight-threatening inflammation.
Key findings
- Route shapes immune response: subretinal delivery produces a weaker humoral response than intravitreal delivery, while some studies found subretinal delivery induces stronger inflammatory reactions; suprachoroidal delivery has a weaker humoral response than intravitreal but lacks known immune privilege. In the INFINITY trial of intravitreal AAV for diabetic macular edema, patients received high virus dose (N=12), lower virus dose (N=13), or aflibercept (N=9); 3 high-dose patients developed late-onset significant inflammation including panuveitis with hypotony, none in the low-dose or aflibercept groups did, and 2 high-dose patients required mycophenolate.
- Vector dose correlates with inflammation in several trials: Cukras et al. gave AAV8 RS1 intravitreally at 1×10⁹, 1×10¹⁰, and 1×10¹¹ viral particles/eye to nine XLRS patients and found dose-dependent ocular inflammation and dose-dependent serum anti-AAV8 antibodies, with inflammation resolving on oral/topical corticosteroids. Le Meur et al. gave subretinal AAV2 in RPE65-LCA at low (1.22–2×10¹⁰) or high (3.27–4.8×10¹⁰) viral genomes to nine patients; mild anterior chamber protein flare occurred in only 3 patients at the highest dose and resolved after 14 days with local/systemic steroids.
- The FDA-approved voretigene neparvovec trial enrolled 29 pediatric patients older than 3 years with LCA and visual acuity of 20/60 or less, randomized 2:1 to intervention or control; it improved functional vision, had no treatment-related serious adverse events, and mild ocular inflammation occurred in only 2 patients (10%) and resolved.
- AAV seroprevalence and vector constituents matter: about 70% of the normal population has preexisting antibodies against AAV2 versus about 38% against AAV8; antiviral antibodies correlate with minimal or absent gene expression. Timmers et al. found anterior segment inflammation depended on the viral genome, empty capsids did not induce anterior reaction, both full particles and empty capsids induced vitreal inflammation, and antibodies were generated regardless of genome presence.
Methods
- Design: narrative literature review focused on ocular gene therapy and associated immune/inflammatory responses.
- Data: synthesis of preclinical and clinical studies and clinical trials covering viral vectors (adenovirus, AAV, lentivirus), non-viral vectors, ocular disease applications, delivery routes (intravitreal, subretinal, suprachoroidal, electrotransfection), dose/constituent effects, and inflammation management.
- Analysis: qualitative synthesis with referenced tables/figures (Table 1, Table 2, Figure 1); no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described in the provided text.
Limitations
- Paper-stated: further investigations are required to elucidate inflammatory reactions and their optimal management after ocular gene therapy; suprachoroidal delivery needs more study regarding its immune/inflammatory profile; no published data exist on electrotransfection safety in human eyes; small patient numbers may explain why some studies did not detect dose-dependent ocular inflammation; Yiu et al.’s suprachoroidal comparison had a small sample size and was performed in non-human primates.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, formal inclusion/exclusion criteria, risk-of-bias assessment, or quantitative synthesis.
- Evident from the text: evidence is drawn from heterogeneous preclinical and clinical studies, including animal and non-human primate models, with varying vectors, doses, routes, endpoints, and underlying diseases, which limits generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
61 Valid · 11 Not valid · 51 Not checked · 27 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Adenovirus has fallen out of favor due to the resulting robust immune response that causes inflammation and elimination of the transduced cells.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Introduction > Viral Vectors
What the sources say
- Partly supportedcites [8] Gregory, 2011, Future Virol sourceExperimental — accuracy not yet measured
The Abstract says immune responses increase toxicity and limit transgene expression; it specifically links adaptive responses to elimination of transduced cells. But the section “Attempts to modify AdV vectors to diminish immune responses” says adenoviral vectors are commonly used for gene therapy, so the claim that adenovirus has fallen out of favor overstates the paper’s account. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The presence of antiviral Abs has been correlated with minimal or absent gene expression following gene therapy.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Introduction > Viral Vectors
What the sources say
- Supportedcites [21] Kotterman, 2015, Gene Ther source
The Results (‘Effect of Pre-Injection Anti-AAV2 Antibodies on Expression’) report that neutralizing antibody titers in monkeys were associated with weak or no transgene expression after intravitreal AAV delivery. The Discussion likewise describes a correlation with weak, decaying, or no expression. The cited finding concerns anti-AAV antibodies in this gene-therapy setting. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, there is still cross-reactivity of anti-AAV Abs against different serotypes.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Introduction > Viral Vectors
What the sources say
- Supportedcites [21] Kotterman, 2015, Gene Ther source
The Results section, “Cross-Reactivity of Antibodies to Various AAV Serotypes Pre-Infection vs. Post-Infection,” reports that antibody titers against AAV5, AAV8, and AAV9 increased after administration of other serotypes. The Discussion likewise states that administering one of AAV2, AAV8, or AAV9 increased titers against all three. This supports the claimed cross-reactivity, though the paper notes that responses vary by serotype. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“AAVs can be rapidly eliminated by the humoral immune response in patients who have previously been exposed to the virus.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Introduction > Viral Vectors
What the sources say
- Partly supportedcites [22] Wan, 2015, Mol Med Rep sourceExperimental — accuracy not yet measured
Section 2 (page unavailable) says gene vectors may be rapidly degraded by the immune system, and Section 5 says systemically delivered viral vectors may trigger host antiviral responses. The review does not establish that a humoral response rapidly eliminates AAV specifically in patients previously exposed to the virus. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Yet, the intravitreal vector approach has still shown a different and distinct immune response from subretinal vector delivery.74”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Modes of Delivery of Vector Therapy and Associated Ocular Inflammation > Intravitreal Delivery
What the sources say
- Supportedcites [74] Reichel, 2018, Invest Ophthalmol Vis Sci source
The Conclusions (p. 1) report no significant humoral antibody response after subretinal AAV8 delivery in the studied primates and patients, but a substantial response after intravitreal delivery. The Discussion (p. 5) likewise identifies a higher risk of humoral immune responses with intravitreal injection. The paper supports the comparison specifically for humoral immunity. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
92 more claims · 40 with their cited sources checked
Create a free account to see all 150 claims and every source verdict.
- It may state two separate claims as one. 48
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, the INFINITY trial was halted as several patients developed panuveitis with hypotony and vision loss four to nine months after treatment (Cheng and Punzo, 2022; Ghoraba et al., 2022).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Ghoraba et al., 2022
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which in turn is less likely to cause excessive inflammatory and immune responses when delivered to this organ [76].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Effect of Vector Dose and Constituents on the Type of Ocular Inflammation > Viral Capsid and Genome
“inflammation in the anterior segment is dependent on the presence of the genome while viral particles with no genome (empty capsids) did not induce an anterior segment reaction.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Effect of Vector Dose and Constituents on the Type of Ocular Inflammation > Relationship Between Viral Dose and Ocular Inflammation
“No or weak correlation was found between the dose and degree of anterior segment inflammation (which was incited by the capsids only), while a strong correlation was noticed with vitreal inflammation (incited by both the genome and capsid).”
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.(4,87,88) The technique itself requires significant surgical experience.”
BackgroundRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 10×
“Gene therapy for ocular diseases has already been approved by the United States Food and Drug Administration (FDA) to treat pediatric patients with Leber congenital amaurosis harboring a particular gene deficiency, named RPE65.(4) Multiple promising clinical trials are currently being conducted for many other ocular d…”
BackgroundMethodInfluentialRaper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498 · cited 1×
“Severe side effects have been reported using adenovirus, as severe as death of a patient with systemic fever and liver damage in a clinical trial for metabolic disease.(9) Although it does not usually replicate inside hosts, a replication-competent virus can be inadvertently created by combination of adenoviral derive…”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“Therefore, there is a lower percentage of humans with Abs against it (around 38%).(20) The presence of antiviral Abs has been correlated with minimal or absent gene expression following gene therapy.”
BackgroundHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761 · cited 2×
“The non-viral vector approach uses different chemical and physical methods to deliver the therapeutic genetic material.(1) While gene therapy is used to treat inherited diseases with loss of function mutations, it can also be used to treat acquired diseases.”
BackgroundRole of Inflammation in Diabetic Retinopathy
Rübsam, A., Parikh, S., & Fort, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040942 · Cited by 750
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 2×
“Such approach may be beneficial in cases where the targeted cells are not limited only to the macula.(65,66) There are two main limitations of the intravitreal route: the inability to transduce outer retina layers and possible immune and inflammatory reaction.”
BackgroundJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Gene Therapy for Cancer: What Have We Done and Where Are We Going?
Roth, J. A., & Cristiano, R. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.21 · Cited by 635 · cited 1×
“Although it does not usually replicate inside hosts, a replication-competent virus can be inadvertently created by combination of adenoviral derived vectors with pre-existing adenoviral genome in the targeted cells, causing active systemic adenoviral infection in the patient.(10)”
BackgroundMurine leukemia induced by retroviral gene marking
Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 525
Inner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357 · cited 2×
“Vectors delivered via the intravitreal route have limited ability to transduce the outer retina possibly due to the internal limiting membrane (ILM), evidenced by the improvement of outer retinal transduction after removing or degrading the ILM.(68,69) However, other studies”
BackgroundInfluentialUsher syndrome: Hearing loss, retinal degeneration and associated abnormalities
Mathur, P., & Yang, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.020 · Cited by 330
Seabra, M. C., Brown, M. S., Slaughter, C. A., Südhof, T. C., & Goldstein, J. L. (1992) · Cell · doi:10.1016/0092-8674(92)90253-9 · Cited by 300
Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268 · cited 4×
“For example, Cukras et al found a dose-dependent response of ocular inflammation.(41) They evaluated the safety of AAV8 as the vector for delivery of RS1 gene in patients with XLRS caused by RS1 gene mutations in a phase I/II an open-label clinical trial.”
BackgroundInfluentialA comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262 · cited 1×
“Most of the retinal genetic diseases are due to defects in the RPE or photoreceptor cells.(67) Vectors delivered via the intravitreal route have limited ability to transduce the outer retina possibly due to the internal limiting membrane (ILM), evidenced by the improvement of outer retinal transduction after removing…”
BackgroundPhilippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., & Serguera, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606197103 · Cited by 249
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Gene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Pharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213 · cited 4×
“Adenovirus offers multiple advantages, including broad range of tissue tropism (transduction of both retina and anterior segment), a well-characterized genome, ease of genetic manipulation, capacity of carrying large genes, nonreplicative nature in a host, and producibility at a large scale.(3,7) Although adenovirus w…”
BackgroundInfluentialKlimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210 · cited 1×
“Such approach may be beneficial in cases where the targeted cells are not limited only to the macula.(65,66) There are two main limitations of the intravitreal route: the inability to transduce outer retina layers and possible immune and inflammatory reaction.”
BackgroundNovel AAV serotypes for improved ocular gene transfer
Lebherz, C., Maguire, A., Tang, W., Bennett, J., & Wilson, J. M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1126 · Cited by 208 · cited 1×
“Bennett et al have reported that AAV2 and AAV8 can infect retinal cells from the vitreous, but it was limited to the inner retina.(12) AAV2 has also been used effectively through a subretinal injection to transduce retinal pigment”
BackgroundGene Therapy for Leber Hereditary Optic Neuropathy
Guy, J., Feuer, W. J., Davis, J. L., Porciatti, V., Gonzalez, P. J., Koilkonda, R. D., Yuan, H., Hauswirth, W. W., & Lam, B. L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.016 · Cited by 204
Technique of retinal gene therapy: delivery of viral vector into the subretinal space
Xue, K., Groppe, M., Salvetti, A. P., & MacLaren, R. E. (2017) · Eye · doi:10.1038/eye.2017.158 · Cited by 191 · cited 1×
“Detachment of the macula is achieved by injecting balanced saline solution followed by vector injection in the preformed bleb.(14,83) Using the subretinal approach to deliver vector therapy is well established as it has many advantages.”
BackgroundEfficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis
Yeh, S., Khurana, R. N., Shah, M., Henry, C. R., Wang, R. C., Kissner, J. M., Ciulla, T. A., & Noronha, G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.01.006 · Cited by 191
Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study
Campochiaro, P. A., Lauer, A. K., Sohn, E. H., Mir, T. A., Naylor, S., Anderton, M. C., Kelleher, M., Harrop, R., Ellis, S., & Mitrophanous, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.117 · Cited by 186 · cited 1×
“The safety of subretinally delivered lentiviral EIAV vector expressing endostatin and angiostatin for neovascular AMD has been established with well-tolerated doses, no dose-limiting toxicities, and little to no ocular inflammation.(30) Intravitreal injection of AAV carrying aflibercept gene has also shown very promis…”
Background(2008) · PubMed Central · Cited by 183
Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21587 · Cited by 182
Fischer, M. D., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Ochakovski, G. A., Klein, R., Schoen, C., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.1032 · Cited by 177
Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience
Dimopoulos, I. S., Hoang, S. C., Radziwon, A., Binczyk, N. M., Seabra, M. C., MacLaren, R. E., Somani, R., Tennant, M. T. S., & MacDonald, I. M. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.06.011 · Cited by 175 · cited 1×
“It was reported at least in two human subjects in two different studies: one study had a subject who suffered from irreversible photoreceptor and vision loss despite steroid use, and another study demonstrated the adverse event in one subject but fortunately resolved following oral steroid treatment.(14,93) It was als…”
ResultCannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment
Olsen, T. W., Feng, X., Wabner, K., Conston, S. R., Sierra, D. H., Folden, D. V., Smith, M. E., & Cameron, J. D. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.05.045 · Cited by 171
Kotterman, M. A., Yin, L., Strazzeri, J. M., Flannery, J. G., Merigan, W. H., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2014.115 · Cited by 169 · cited 3×
“However, there is still cross-reactivity of anti-AAVAbs against different serotypes.(21) AAVs can be rapidly eliminated by the humoral immune response in patients who have previously been exposed to the virus.”
BackgroundYiu, G., Chung, S. H., Mollhoff, I. N., Nguyen, U. T., Thomasy, S. M., Yoo, J., Taraborelli, D., & Noronha, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.002 · Cited by 153 · cited 8×
“While the intravitreal route did not cause significant posterior segment inflammation in the form of chorioretinitis, both suprachoroidal and subretinal routes elicited it.(78) There has been no evidence of a deviant immune response in the suprachoroidal space.”
BackgroundResultInfluentialConstable, I. J., Pierce, C. M., Lai, C.-M., Magno, A. L., Degli-Esposti, M. A., French, M. A., McAllister, I. L., Butler, S., Barone, S. B., Schwartz, S. D., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.016 · Cited by 152 · cited 2×
“Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.(4,87,88) The technique itself requires significant surgical experience.”
BackgroundEvaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147 · cited 1×
“As mentioned above, few studies found that subretinal route can induce more inflammation compared to the intravitreal route.(13,77,78) One may consider this secondary to the surgical technique itself rather than the immune response to the vector; however, Reichel et al showed that subretinal delivery of a vector cause…”
ResultAAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye
Reichel, F. F., Dauletbekov, D. L., Klein, R., Peters, T., Ochakovski, G. A., Seitz, I. P., Wilhelm, B., Ueffing, M., Biel, M., Wissinger, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.018 · Cited by 145 · cited 10×
“One may consider this secondary to the surgical technique itself rather than the immune response to the vector; however, Reichel et al showed that subretinal delivery of a vector caused more inflammation than just performing the same surgical procedure without injecting a vector.(13) Nevertheless, to our knowledge, no…”
BackgroundMethodResultInfluentialAAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression
Ding, K., Shen, J., Hafiz, Z., Hackett, S. F., Silva, R. L. E., Khan, M., Lorenc, V. E., Chen, D., Chadha, R., Zhang, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129085 · Cited by 141 · cited 2×
“Studies on animals other than NHPs showed that the suprachoroidal route can be used effectively to infect photoreceptors.(95,101) Another issue is the non-sustainability of gene expression via this route, which can be gradually diminished over 3 months.”
BackgroundResultChung, D. C., & Traboulsi, E. I. (2009) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.10.004 · Cited by 138 · cited 1×
“Despite the significant visual impairment in LCA, retinal cells and photoreceptors are relatively spared.(56) Therefore, RPE65-mediated LCA has shown to be a favorable candidate for ocular gene therapy as it requires a certain amount of viable cells to be effective.”
BackgroundSafety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis
Le Meur, G., Lebranchu, P., Billaud, F., Adjali, O., Schmitt, S., Bézieau, S., Péréon, Y., Valabregue, R., Ivan, C., Darmon, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.014 · Cited by 137
Genetic Etiology and Clinical Consequences of Complete and Incomplete Achromatopsia
Thiadens, A. A. H. J., Slingerland, N. W. R., Roosing, S., van Schooneveld, M. J., van Lith-Verhoeven, J. J. C., van Moll-Ramirez, N., van den Born, L. I., Hoyng, C. B., Cremers, F. P. M., & Klaver, C. C. W. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.03.053 · Cited by 131 · cited 1×
“Achromatopsia For achromatopsia, there are six different gene mutations (CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6) of which CNGA3 and CNGB3 are the most common.(55) Clinical trials are being conducted targeting these two genes with an AAV vector through subretinal injection.”
BackgroundBonnet, C., Augustin, S., Ellouze, S., Bénit, P., Bouaita, A., Rustin, P., Sahel, J.-A., & Corral-Debrinski, M. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.04.018 · Cited by 130 · cited 1×
“As delivering genes into the ganglion cell mitochondria is difficult, “allotopic expression” strategy (mitochondrial gene expression in nucleus) has been developed.(61) Different trials have demonstrated the safety and efficacy of gene therapy using an AAV vector, delivered through an intravitreal route, for LHON.”
BackgroundLentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B
Hashimoto, T., Gibbs, D., Lillo, C., Azarian, S. M., Legacki, E. L., Zhang, X., Yang, X.-J., & Williams, D. S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302897 · Cited by 125 · cited 1×
“Similar to Stargardt disease, lentiviruses are required to deliver the large-sized genetic material.(51,52) A single clinical trial was conducted for Usher syndrome with a mutation in MYO7A gene using a lentivirus vector through a subretinal injection, but it was terminated.”
BackgroundOcular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120 · cited 4×
“The irreversibility and unpredictable longevity of gene therapy effects highlights the lack of control once the treatment is administered.(6) Different vector types and subtypes induce variable immune and inflammatory responses.”
BackgroundInfluentialBinley, K., Widdowson, P., Loader, J., Kelleher, M., Iqball, S., Ferrige, G., de Belin, J., Carlucci, M., Angell-Manning, D., Hurst, F., et al. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11871 · Cited by 115 · cited 1×
“However, this whitening (which probably represented a form of intraocular inflammation) was transient and resolved with treatment.(28) In general, multiple studies have shown that lentiviruses are relatively safe and can result in effective and sustained gene transduction for a significant time.”
ResultOcular gene delivery using lentiviral vectors
Balaggan, K. S., & Ali, R. R. (2011) · Gene Therapy · doi:10.1038/gt.2011.153 · Cited by 113 · cited 1×
“Similar to the two previous vectors, it possesses the ability to induce a stable transduction in both dividing and non-dividing cells in a broad range of target organs.(23) Lentiviral vectors are derived from primate lentiviruses human immunodeficiency virus (HIV), equine infectious anemia virus (EIAV) and simian immu…”
ResultImmune response following intraocular delivery of recombinant viral vectors
Bennett, J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302030 · Cited by 111 · cited 4×
“Adenovirus offers multiple advantages, including broad range of tissue tropism (transduction of both retina and anterior segment), a well-characterized genome, ease of genetic manipulation, capacity of carrying large genes, nonreplicative nature in a host, and producibility at a large scale.(3,7) Although adenovirus w…”
BackgroundInfluentialRetinitis Pigmentosa: Progress and Perspective
Zhang, Q. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000227 · Cited by 109 · cited 2×
“Retinitis Pigmentosa (RP) is a heterogeneous disease, and it occurs in an autosomal recessive (AR) pattern in 50–60% of the cases.48 The most common genes include RPGR (retinitis pigmentosa GTPase regulator) which accounts for ~70% of X-linked RP; rhodopsin (RHO) which causes ~25% of AD RP, and the Usherin2A (USH2A) g…”
BackgroundOptogenetic approaches to vision restoration
Simunovic, M. P., Shen, W., Lin, J. Y., Protti, D. A., Lisowski, L., & Gillies, M. C. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2018.09.003 · Cited by 109 · cited 1×
“This approach has the potential to improve visual perception in cases of RP and other inherited retinal diseases where the photoreceptors are severely damaged.(50) Usher syndrome displays AR inheritance with different large-sized causative genes, including MYO7A, USH2A and GPR98.”
BackgroundSeitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108
Chen, M., Li, X., Liu, J., Han, Y., & Cheng, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.021 · Cited by 105
In vivo–directed evolution of adeno-associated virus in the primate retina
Byrne, L. C., Day, T. P., Visel, M., Strazzeri, J. A., Fortuny, C., Dalkara, D., Merigan, W. H., Schaffer, D. V., & Flannery, J. G. (2020) · JCI Insight · doi:10.1172/jci.insight.135112 · Cited by 104
Bouquet, C., Vignal Clermont, C., Galy, A., Fitoussi, S., Blouin, L., Munk, M. R., Valero, S., Meunier, S., Katz, B., Sahel, J. A., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6902 · Cited by 104
Takahashi, K., Igarashi, T., Miyake, K., Kobayashi, M., Yaguchi, C., Iijima, O., Yamazaki, Y., Katakai, Y., Miyake, N., Kameya, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.008 · Cited by 99 · cited 2×
“Vectors delivered via the intravitreal route have limited ability to transduce the outer retina possibly due to the internal limiting membrane (ILM), evidenced by the improvement of outer retinal transduction after removing or degrading the ILM.(68,69) However, other studies”
BackgroundInfluentialRetinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h−/− mouse
Byrne, L. C., Öztürk, B. E., Lee, T., Fortuny, C., Visel, M., Dalkara, D., Schaffer, D. V., & Flannery, J. G. (2014) · Gene Therapy · doi:10.1038/gt.2014.31 · Cited by 96
Non-viral ocular gene therapy: Potential ocular therapeutic avenues
Bloquel, C., Bourges, J., Touchard, E., Berdugo, M., BenEzra, D., & Béhar‐Cohen, F. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.023 · Cited by 93 · cited 1×
“Non-viral vectors are used to transfer large DNA-like plasmids, small DNA (eg, oligodeoxynucleotides), and RNA molecules through different chemical and physical methods.(31) Chemical methods include lipid-based delivery systems, polymers, and cell-penetrating peptides.”
BackgroundBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92 · cited 2×
“The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.(18)”
BackgroundGuimaraes, T. A. C. D., Georgiou, M., Bainbridge, J. W. B., & Michaelides, M. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316195 · Cited by 91 · cited 1×
“cells can produce the desired drugs in vivo.(2) This concept has considerable potential; patients can be treated once, and their tissues are transformed into bio-factories that produce the medications indefinitely.”
BackgroundImplications of the Innate Immune Response to Adenovirus and Adenoviral Vectors
Gregory, S. M., Nazir, S. A., & Metcalf, J. P. (2011) · Future Virology · doi:10.2217/fvl.11.6 · Cited by 89
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88 · cited 1×
“In addition, the assessment of treatment implications can be performed non-invasively via diagnostic imaging, and the second eye can be used as a control group.(34) Several studies are focusing on possible gene therapies for an array of ocular diseases from the cornea to the retina.”
Sonoda, K., Sakamoto, T., Qiao, H., Hisatomi, T., Oshima, T., Tsutsumi‐Miyahara, C., Exley, M., Balk, S. P., Taniguchi, M., & Ishibashi, T. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02239.x · Cited by 87
Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients
Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., et al. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22494 · Cited by 86 · cited 3×
“Other studies also found that gene transduction was achievable if injected in the subretinal space even if the subjects have neutralizing antibodies.(74,92) This beneficial immune response has raised the question of whether it is better not to use steroids with a subretinal injection, as this would theoretically negat…”
BackgroundGene therapy for ocular diseases
Liu, M. M., Tuo, J., & Chan, C.-C. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.174912 · Cited by 82 · cited 2×
“Similar to adenovirus, AAVs can also infect dividing and non-dividing cells.(15,16) AAVs’ limited capacity to carry large-sized genetic material restricts their use in gene delivery for some diseases that are coded by large genes such as Usher syndrome.”
BackgroundNon-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80 · cited 3×
“Short-term expression of the transduced genetic material can be considered as a major disadvantage of this method.(6,32)”
BackgroundAAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models
Vasireddy, V., Mills, J. A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A. D., Alexandrov, K., Zhou, S., Maguire, A. M., Chung, D. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061396 · Cited by 79
Timmers, A. M., Newmark, J. A., Turunen, H. T., Farivar, T., Liu, J., Song, C., Ye, G.-J., Pennock, S., Gaskin, C., Knop, D. R., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.144 · Cited by 77 · cited 3×
“As mentioned, Timmers et al(16) found that the relationship between the dose and the inflammationmay be dependent on the site of intraocular inflammation.(16) No or weak correlation was found between the dose and degree of anterior segment inflammation (which was incited by the capsids only), while a strong correlatio…”
BackgroundMoreno-Montañés, J., Sádaba, B., Ruz, V., Gómez-Guiu, A., Zarranz, J., González, M. V., Pañeda, C., & Jimenez, A. I. (2014) · Molecular Therapy · doi:10.1038/mt.2013.217 · Cited by 76
Gene therapy for Stargardt disease associated with ABCA4 gene
Han, Z., Conley, S. M., & Naash, M. I. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_90 · Cited by 74 · cited 1×
“Stargardt Disease Stargardt disease is caused by ABCA4 mutations leading to accumulation of lipofuscin pigment inside the RPE causing degeneration of both RPE and photoreceptor cells.(42) A phase I/II clinical trial investigated the utility of EIAV-vector carrying the ABCA4 gene that is delivered through the subretina…”
BackgroundPharmacological management of ocular hypertension: current approaches and future prospective
Bucolo, C., Salomone, S., Drago, F., Reibaldi, M., Longo, A., & Uva, M. G. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.09.012 · Cited by 71
Glaucoma: Present Challenges and Future Trends
Bettin, P., & Di Matteo, F. (2013) · Ophthalmic Research · doi:10.1159/000348736 · Cited by 69 · cited 1×
“Glaucoma As 72% of the cases with primary open-angle glaucoma are hereditary and there is a monogenic inheritance component in juvenile-onset open-angle glaucoma, gene therapy may be beneficial.(36) Preclinical and Phase I studies have shown that gene therapy using small interference RNA (siRNA) that suppresses ß2-adr…”
BackgroundAnand, V., Duffy, B., Yang, Z., Dejneka, N. S., Maguire, A. M., & Bennett, J. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0525 · Cited by 69 · cited 4×
“Furthermore, Anand et al reported suppression of pre-existing cellular immune response to certain antigens after injecting them into the subretinal space.(19) Other studies also found that gene transduction was achievable if injected in the subretinal space even if the subjects have neutralizing antibodies.”
BackgroundInfluentialTouchard, E., Berdugo, M., Bigey, P., El Sanharawi, M., Savoldelli, M., Naud, M.-C., Jeanny, J.-C., & Behar-Cohen, F. (2012) · Molecular Therapy · doi:10.1038/mt.2011.304 · Cited by 63
Peden, M. C., Min, J., Meyers, C., Lukowski, Z., Li, Q., Boye, S. L., Levine, M., Hauswirth, W. W., Ratnakaram, R., Dawson, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017140 · Cited by 63 · cited 1×
“Studies on animals other than NHPs showed that the suprachoroidal route can be used effectively to infect photoreceptors.(95,101) Another issue is the non-sustainability of gene expression via this route, which can be gradually diminished over 3 months.”
BackgroundSuprachoroidal gene transfer with nonviral nanoparticles
Shen, J., Kim, J., Tzeng, S. Y., Ding, K., Hafiz, Z., Long, D., Wang, J., Green, J. J., & Campochiaro, P. A. (2020) · Science Advances · doi:10.1126/sciadv.aba1606 · Cited by 63 · cited 1×
“This route is also being investigated for delivering non-viral vectors with promising results in animals.(94) Different techniques are being used for suprachoroidal drug delivery.”
BackgroundBinley, K., Widdowson, P. S., Kelleher, M., de Belin, J., Loader, J., Ferrige, G., Carlucci, M., Esapa, M., Chipchase, D., Angell-Manning, D., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.008 · Cited by 61
(1991) · PubMed · Cited by 59
Chan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema
Barakat, M. R., Wykoff, C. C., Gonzalez, V., Hu, A., Marcus, D., Zavaleta, E., & Ciulla, T. A. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2020.08.007 · Cited by 55
Progress on ocular siRNA gene‐silencing therapy and drug delivery systems
Jiang, J., Zhang, X., Tang, Y., Li, S., & Chen, J. (2021) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12561 · Cited by 54 · cited 1×
“Such viral composition is particularly useful for diseases with large causative genes such as Stargardt disease and Usher syndrome.(22,25,26) Lentiviruses are possibly more immunogenic than AAVs.”
BackgroundAdeno-Associated Virus Mediated Gene Therapy for Corneal Diseases
Bastola, P., Song, L., Gilger, B. C., & Hirsch, M. L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080767 · Cited by 52
Cwerman-Thibault, H., Augustin, S., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2014) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2013.11.011 · Cited by 49 · cited 1×
“Optic Nerve Diseases Leber Hereditary Optic Neuropathy Leber hereditary optic neuropathy (LHON), an inherited mitochondrial optic neuropathy related to retinal ganglion cell death, is most commonly linked to ND1 (G3460A), ND4 (G11778A), and ND6 (T14484C) gene mutations.(60) As delivering genes into the ganglion cell m…”
BackgroundCombined Rod and Cone Transduction by Adeno-Associated Virus 2/8
Manfredi, A., Marrocco, E., Puppo, A., Cesi, G., Sommella, A., Corte, M. D., Rossi, S., Giunti, M., Craft, C. M., Bacci, M. L., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.154 · Cited by 47
Parker, M. A., Choi, D., Erker, L. R., Pennesi, M. E., Yang, P., Chegarnov, E. N., Steinkamp, P. N., Schlechter, C. L., Dhaenens, C.-M., Mohand-Said, S., et al. (2016) · Translational Vision Science & Technology · doi:10.1167/tvst.5.5.10 · Cited by 46 · cited 1×
“A phase I/II clinical trial investigated the utility of EIAV-vector carrying the ABCA4 gene that is delivered through the subretinal route, but it was terminated in 2015.(43) Other clinical trials for Stargardt Disease are being planned.”
BackgroundKalesnykas, G., Kokki, E., Alasaarela, L., Lesch, H. P., Tuulos, T., Kinnunen, K., Uusitalo, H., Airenne, K., & Yla-Herttuala, S. (2017) · Current Gene Therapy · doi:10.2174/1566523217666171003170348 · Cited by 43 · cited 2×
“Such viral composition is particularly useful for diseases with large causative genes such as Stargardt disease and Usher syndrome.22,25,26 Lentiviruses are possibly more immunogenic than AAVs.27 Binley et al found that 5 out of 6 non-human primates that were injected with EIAV in their subretinal space developed a pe…”
BackgroundGene Transfer to Rabbit Retina with Electron Avalanche Transfection
Chalberg, T. W., Vankov, A., Molnar, F. E., Butterwick, A. F., Huie, P., Calos, M. P., & Palanker, D. V. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0092 · Cited by 42
Ochakovski, G. A., Peters, T., Michalakis, S., Wilhelm, B., Wissinger, B., Biel, M., Bartz-Schmidt, K. U., Fischer, M. D., & for the RD-CURE Consortium (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22402 · Cited by 38 · cited 1×
“Ochacovski et al(89) have shown that subretinal injection, in NHPs, can cause mild thinning of the outer layers of the fovea in comparison with an intravitreal injection of the same vector.(89,90) However, the difference was not clinically significant.”
ResultPathogenic mechanisms and the prospect of gene therapy for choroideremia
Dimopoulos, I. S., Chan, S., MacLaren, R. E., & MacDonald, I. M. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1046434 · Cited by 37 · cited 1×
“There are some challenges for gene therapy in choroideremia, including insufficient resemblance of animal models to functional and morphological manifestations of the disease, and uncertainty of which retinal layer is affected most.(45,46) Gene therapy outcomes for choroideremia have been less successful than RPE65-re…”
BackgroundGene therapy for ocular diseases meditated by ultrasound and microbubbles (Review)
WAN, C., LI, F., & LI, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4054 · Cited by 36
Pepose, J. S., & Leib, D. A. (1994) · PubMed · Cited by 34
Naik, S., Shreya, A. B., Raychaudhuri, R., Pandey, A., Lewis, S. A., Hazarika, M., Bhandary, S. V., Rao, B. S. S., & Mutalik, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118712 · Cited by 33
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
SUPRACHOROIDAL DRUG INFUSION FOR THE TREATMENT OF SEVERE SUBFOVEAL HARD EXUDATES
Rizzo, S., Ebert, F. G., Bartolo, E. D., Barca, F., Cresti, F., Augustin, C., & Augustin, A. (2012) · Retina · doi:10.1097/iae.0b013e3182278b0e · Cited by 32
Touchard, E., Benard, R., Bigot, K., Laffitte, J.-D., Buggage, R., Bordet, T., & Behar-Cohen, F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.013 · Cited by 32
Nuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00287-1 · Cited by 29 · cited 1×
“Such viral composition is particularly useful for diseases with large causative genes such as Stargardt disease and Usher syndrome.(22,25,26) Lentiviruses are possibly more immunogenic than AAVs.”
BackgroundMarangoni, D., Wu, Z., Wiley, H. E., Zeiss, C. J., Vijayasarathy, C., Zeng, Y., Hiriyanna, S., Bush, R. A., Wei, L. L., Colosi, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.067 · Cited by 29 · cited 1×
“Studies on humans and NHPs have demonstrated consistently that intravitreal delivery of vectors induces a significant humoral immune response.(13,21,75,76) The response is marked by the production of Abs, which may not lead to inflammation, but can significantly reduce the efficacy of treatment by attacking and elimin…”
BackgroundNew Frontiers of Corneal Gene Therapy
Iorio, E. D., Barbaro, V., Alvisi, G., Trevisan, M., Ferrari, S., Masi, G., Nespeca, P., Ghassabian, H., Ponzin, D., & Palù, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.026 · Cited by 28
Safety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates
Weed, L., Ammar, M. J., Zhou, S., Wei, Z., Serrano, L. W., Sun, J., Lee, V., Maguire, A. M., Bennett, J., & Aleman, T. S. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.011 · Cited by 27 · cited 2×
“Other studies also found that gene transduction was achievable if injected in the subretinal space even if the subjects have neutralizing antibodies.(74,92) This beneficial immune response has raised the question of whether it is better not to use steroids with a subretinal injection, as this would theoretically negat…”
BackgroundKowalczuk, L., Touchard, E., Camelo, S., Naud, M.-C., Castaneda, B., Brunel, N., Besson-Lescure, B., Thillaye-Goldenberg, B., Bigey, P., BenEzra, D., et al. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3027 · Cited by 25 · cited 1×
“short electrical pulses (electrotransfection) are highly efficient in transducing the ciliary body to produce the desired drug autonomously.(6,32,33) The main advantages of non-viral methods include the lower risk of immune stimulation and insertional mutagenesis (as most do not integrate with chromosomes), the abilit…”
Background(1987) · PubMed · Cited by 22
MacDonald, I. M., Moen, C., Duncan, J. L., Tsang, S. H., Cehajic-Kapetanovic, J., & Aleman, T. S. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.3.17 · Cited by 20 · cited 1×
“amaurosis (LCA).(47) There are currently nine clinical trials registered on ClinicalTrials.”
BackgroundOcular Gene Therapy: From Fantasy to Foreseeable Reality
Zack, D. J. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090110043019 · Cited by 19 · cited 1×
“The OPTIC trial, which used the same vector type in neovascular AMD patients, did also show a dose dependent inflammatory response but much less in severity when compared with INFINITY trial, implying that the underlying disease should also be considered a factor when assessing the risk of inflammation.(80,81,109) Few…”
ResultCorrection: AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models
Vasireddy, V., Mills, J. A., Gaddameedi, R., Basner‐Tschakarjan, E., Köhnke, M., Black, A. D., Alexandrov, K. A., Zhou, S., Maguire, A. M., Chung, D. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129982 · Cited by 2 · cited 1×
“There are some challenges for gene therapy in choroideremia, including insufficient resemblance of animal models to functional and morphological manifestations of the disease, and uncertainty of which retinal layer is affected most.(45,46) Gene therapy outcomes for choroideremia have been less successful than RPE65-re…”
Background
Research works printed but not linked: 7
- Pepose, 1994, Invest Ophthalmol Vis Sci, 35, 2662
- Jiang, 1991, Invest Ophthalmol Vis Sci, 32, 224
- Atherton, 1987, Invest Ophthalmol Vis Sci, 28, 859
- Li, 2008, Mol Vis, 14, 1760
- Wykoff Obotii CC. Intravitreal gene therapy for diabetic macular edema with ADVM-022: first-time data presentation of prospective, randomized phase 2 INFINITY trial [Conference presentation]. American Society of Retina Specialists Annual Scientific Meeting; October 8-12, 2021; 2021; San Antonio, Texas, USA.
- Dante Pieramici O. ADVM-022 intravitreal gene therapy for neovascular AMD: phase 1 OPTIC study [Conference presentation]. American Society of Retina Specialists Annual Scientific Meeting; October 8-12, 2021; 2021; San Antonio, Texas, USA.
- Bucher, 2021, Prog Retin Eye Res, 83, 100915, 10.1016/j.preteyeres.2020.100915 · DOI · Paper page
Cited by
Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies
Nguyen, X., Moekotte, L., Plomp, A. S., Bergen, A. A. B., van Genderen, M. M., & Boon, C. J. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087481 · Cited by 150
“Furthermore, intravitreal and subretinal delivery can induce immune and inflammatory responses, which can typically be managed with steroid therapy, but in rare cases may result in significant ocular inflammation with sight-threatening complications [299].”
BackgroundUpdate on viral gene therapy clinical trials for retinal diseases
Cheng, S.-Y., & Punzo, C. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.159 · Cited by 49
“For a more in-depth review on inflammatory responses seen in ocular gene therapies, we refer the readers to a recently published review on the topic.(139)”
BackgroundMethodEvaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy
Gorovits, B., Azadeh, M., Buchlis, G., Fiscella, M., Harrison, T., Havert, M., Janetzki, S., Jawa, V., Long, B. R., Mahnke, Y. D., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00814-5 · Cited by 52
“These considerations, coupled with the extreme difficulty, if not infeasibility, to acquire ocular immune monitoring samples, would make the detection of a humoral or cellular immune response to an ocular gene therapy of low scientific value, and hence, such assessments may not be required (52, 53).”
BackgroundRowe, L. W., & Ciulla, T. A. (2024) · Genes · doi:10.3390/genes15060720 · Cited by 53
Current developments of gene therapy in human diseases
Liu, F., Li, R., Zhu, Z., Yang, Y., & Lu, F. (2024) · MedComm · doi:10.1002/mco2.645 · Cited by 48
Metadata
- Authors
- Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., Mobasserian, A., DongChau, A. T., Or, C., Yasar, C., Mishra, K., Do, D., & Nguyen, Q. D.
- Affiliations
- Stanford University (US)
- Corresponding author
- Ghoraba, Hashem H
- Akhavanrezayat, Amir
- Karaca, Irmak
- Yavari, Negin
- Lajevardi, Sherin
- Hwang, Jaclyn
- Regenold, Jonathan
- Matsumiya, Wataru
- Pham, Brandon
- Zaidi, Moosa
- Mobasserian, Azadeh
- DongChau, Anthony Toan
- Mishra, Kapil
- Nguyen, Quan Dong
- ORCID
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2022-06
- Volume
- Volume 16
- Pages
- 1753-1771
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC9173725
- OpenAlex
- W4281606199
- Cited by
- 76
- References
- 102
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 20 · 2023: 13 · 2022: 4
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Eye Institute (P30EY026877)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- ocular gene therapy, immune response, ocular inflammation, viral vectors, route of administration, subretinal delivery, intravitreal delivery, humoral immune response, intraocular inflammation, vision loss, immune privilege
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
